<DOC>
	<DOCNO>NCT02911818</DOCNO>
	<brief_summary>This 52 week , single center , open-labeled , randomize control trial . A total 150 subject obesity , free type 1 2 diabetes , well contraindication weight loss , randomly assign one three treatment group : 1 ) lifestyle counseling , currently recommend Centers Medicare Medicaid Services ( CMS ) ( i.e. , CMS-Alone ) ; 2 ) CMS lifestyle counseling plus liraglutide ( i.e. , CMS-Liraglutide ) ; 3 ) CMS-Liraglutide plus portion-controlled diet ( i.e. , Multi-Component Intervention ) . Subjects three group 14 brief ( 15 minute ) lifestyle counsel visit first 24 week , follow monthly visit week 25-52 . This schedule duration counsel visit recommend CMS . Counseling session deliver physician , nurse practitioner register dietitian ( RD ) work consultation former provider . Subjects three group also brief physician visit week 1 , 4 , 8 , 16 , 24 , 36 , 52 ( total 7 visit ) . These visit need subject liraglutide group monitor response medication . These visit include subject CMS-Alone match intensity medical care provide two group . The primary outcome % reduction initial body weight , measure randomization week 52 . Secondary outcome include proportion participant week 52 lose &gt; 5 % , &gt; 10 % , &gt; 15 % initial weight , well % reduction weight week 24 proportion participant meet three categorical weight loss time . The secondary efficacy measure include change ( randomization week 52 ) cardiovascular disease ( CVD ) risk factor , glycemic control , mood , quality life , eat behavior , appetite , sleep , satisfaction weight loss . Safety endpoint include physical examination , adverse event ( AEs ) , standard laboratory test , mental health assess Columbia Suicidality Severity Rating Scale ( C-SSRS ) Patient Health Questionnaire ( PHQ-9 ) . Statistical Analysis . Using sample size equation longitudinal cluster sample , randomization sample 50 subject CMS-Alone , 50 CMS-Liraglutide , 50 Multi-Component Intervention provide &gt; 80 % power detect two primary contrast statistically significant . This estimate allow 20 % attrition 52-week trial , result approximately 40 treatment completers per group . The ITT longitudinal statistical design improve power allow inclusion available data non-completers adjustment possible variance reduce baseline covariates .</brief_summary>
	<brief_title>Lifestyle Modification Liraglutide</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Participants must BMI ≥ 30 ≤ 55 kg/m² 2 . Age ≥ 21 year ≤ 70 year 3 . Eligible female patient : nonpregnant , evidence negative urine dipstick pregnancy test nonlactating surgically sterile postmenopausal , agree continue use accept method birth control study 4 . Ability provide inform consent trialrelated activity 5 . Participants must : primary care provider ( PCP ) responsible provide routine care reliable telephone service communicate study staff understand willing comply studyrelated procedure agree participate study give write informed consent plan remain Philadelphia area next 18 month 1 . Pregnant nursing , plan become pregnant next 18 month , use adequate contraceptive measure 2 . Personal family history medullary thyroid cancer multiple endocrine neoplasia syndrome type 2 3 . Uncontrolled hypertension ( systolic blood pressure ≥ 160 mm Hg diastolic blood pressure ≥ 100 mm Hg ) 4 . Type 1 diabetes 5 . Type 2 diabetes 6 . A fast glucose ≥ 126 mg/dl ( second assessment first elevate value ) 7 . Recent history cardiovascular disease ( e.g. , myocardial infarction stroke within past 6 month ) , congestive heart failure , heart block great first degree 8 . Clinically significant hepatic renal disease 9 . Thyroid disease , control 10 . History malignancy ( except nonmelanoma skin cancer ) past 5 year 11 . Current major depressive episode , active suicidal ideation , history suicide attempt 12 . Psychiatric hospitalization within past 6 month 13 . Selfreported alcohol substance abuse within past 12 month , include atrisk drinking ( current consumption ≥ 14 alcoholic drink per week ) 14 . Use past 3 month medication know induce significant weight loss ( i.e. , prescription weight loss medication ) weight gain ( e.g. , chronic use oral steroid , second generation antipsychotic ) 15 . Loss ≥ 10 lb body weight within past 3 month 16 . History ( plan ) bariatric surgery 17 . Inability walk 5 block comfortably engage form aerobic activity ( e.g. , swim ) 18 . Known suspect allergy trial medication ( ) , excipients , relate product 19 . Hypersensitivity liraglutide product component 20 . The receipt investigational drug within 6 month prior trial 21 . Previous participation trial ( e.g. , randomize failed participate ) 22 . History pancreatitis 23 . Subjects included/excluded accord late updated US PI .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>